- Home
- Publications
- Publication Search
- Publication Details
Title
Trial Watch
Authors
Keywords
-
Journal
OncoImmunology
Volume 3, Issue 2, Pages e27297
Publisher
Informa UK Limited
Online
2014-03-15
DOI
10.4161/onci.27297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
- (2013) B Sherrill et al. BRITISH JOURNAL OF CANCER
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- Cisplatin Resistance Associated with PARP Hyperactivation
- (2013) J. Michels et al. CANCER RESEARCH
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Tremelimumab: a review of development to date in solid tumors
- (2013) Ahmad A Tarhini Immunotherapy
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Decoding cell death signals in liver inflammation
- (2013) Catherine Brenner et al. JOURNAL OF HEPATOLOGY
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Reassessing target antigens for adoptive T-cell therapy
- (2013) Christian S Hinrichs et al. NATURE BIOTECHNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- Trial Watch: Lenalidomide-based immunochemotherapy
- (2013) Michaela Semeraro et al. OncoImmunology
- Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I
- (2013) Max Schnurr et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+head and neck cancer cells
- (2013) Chwee Ming Lim et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- Melanoma and other skin tumors
- (2012) J. Sosman et al. ANNALS OF ONCOLOGY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
- (2012) William Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
- (2012) Saskia J. A. M. Santegoets et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
- (2012) Andrea Wang-Gillam et al. INVESTIGATIONAL NEW DRUGS
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
- (2012) S. S. Kwek et al. JOURNAL OF IMMUNOLOGY
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
- (2012) Antoni Ribas et al. Journal of Translational Medicine
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
- (2012) Andres Forero-Torres et al. LEUKEMIA & LYMPHOMA
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
- (2012) John C. Byrd et al. LEUKEMIA & LYMPHOMA
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
- (2012) L. Senovilla et al. SCIENCE
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
- (2012) Rebecca Waitz et al. OncoImmunology
- Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
- (2012) Adriana J. Michielsen et al. OncoImmunology
- High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator
- (2012) Sveinung W. Sorbye et al. OncoImmunology
- Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy
- (2012) Pascale Hubert et al. OncoImmunology
- Trial Watch: Monoclonal antibodies in cancer therapy
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2012) Erika Vacchelli et al. OncoImmunology
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- Trial watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
- (2012) Timothy Kute et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
- (2012) Erika Vacchelli et al. OncoImmunology
- Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
- (2012) Roch Houot et al. OncoImmunology
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- OX40 and CD30 signals in CD4+ T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T-cell memory but not effector function
- (2011) David R. Withers et al. IMMUNOLOGICAL REVIEWS
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
- (2010) Magdalena Winiarska Frontiers in Bioscience-Landmark
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- Complement and its role in innate and adaptive immune responses
- (2009) Jason R Dunkelberger et al. CELL RESEARCH
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Vaccine trials in melanoma—time for reflection
- (2009) Alexander M. M. Eggermont Nature Reviews Clinical Oncology
- Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
- (2008) J. Hoffmann et al. CANCER RESEARCH
- Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
- (2008) L. M. Weiner et al. CLINICAL CANCER RESEARCH
- Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells
- (2008) Nathalie T. Joncker et al. IMMUNOLOGICAL REVIEWS
- Negative signaling by inhibitory receptors: the NK cell paradigm
- (2008) Eric O. Long IMMUNOLOGICAL REVIEWS
- First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
- (2008) Andrea Molckovsky et al. Journal of Hematology & Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started